Arkolith/Insider Trading/JANX/Form 4

DiRaimondo Thomas

Chief Scientific OfficerJanux Therapeutics, Inc. (JANX) · full profile →Form 4 · filed Jan 2, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$34K
Net Open-Market Flow
-$34K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 2, 2026Sell(S)3K$13.73$34K124K
Jan 2, 2026Grant(A)31K—$0156K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 2, 2026Grant(A)110K—$0110K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002005618-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML